| Literature DB >> 23109868 |
Waqar Ahmad Kaleem1, Muhammad Nisar2, Mughal Qayum3, Muhammad Zia-Ul-Haq4, Achyut Adhikari5, Vincenzo De Feo6.
Abstract
Two new 14-membered cyclopeptide alkaloids, Oxyphylline B (4) and Oxyphylline C (5), along with three known 13-membered cyclopeptide alkaloids, were isolated from stem and roots of Zizyphus oxyphylla Edgew. The compounds were tested for antibacterial activity. Oxyphylline B (4) showed comparatively better antibacterial activities against Escherichia coli (MIC, 5 μg/mL) than other compounds. This compound also exhibited weak antimicrobial activities against Staphylococcus aureus (MIC, 25 μg/mL), Pseudomonas aeruginosa (MIC, 50 μg/mL) and Salmonella typhi (MIC, 50 μg/mL).Entities:
Keywords: Zizyphus oxyphylla Edgew; antibacterial activity; cyclopeptide alkaloids
Mesh:
Substances:
Year: 2012 PMID: 23109868 PMCID: PMC3472760 DOI: 10.3390/ijms130911520
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
Figure 1Isolated cyclopeptides (1–5).
13H-NMR (500 MHz) and 13C NMR (125 MHz) data for Oxyphylline B (4) and Oxyphylline C (5).
| Position | Oxyphylline B (4) | Oxyphylline C (5) | ||
|---|---|---|---|---|
|
|
| |||
| δH (J in Hz) | δC, Multiplicity | δH (J in Hz) | δC, Multiplicity | |
| 1 | - | 158.7, C | - | 156.8, C |
| 3 | 5.45 ddd (7.0, 5.5, 3.0) | 85.3, CH | 5.80 d ( | 83.8, CH |
| 4 | 4.26 d (5.5) | 65.4, CH | 4.80 dd ( | 57.0, CH |
| 5 | - | 172.1, C | 172.0, CO | |
| 6 | 6.90 d (4.0), NH | - | ||
| 7 | 4.10 dd (9.5, 4.0) | 59.2,CH | 3.95 br d ( | 59.8, CH |
| 8 | - | 168.1, C | _ | 167.7, CO |
| 9 | 7.54 d (9.5) | -, NH | 7.51 d ( | _, NH |
| 10 | 6.10 dd (9.5, 7.5) | 126.6, CH | 6.65 dd ( | 126.7, CH |
| 11 | 6.38 d (7.5) | 117.3, CH | 6.42 d ( | 116.7, CH |
| 12 | - | 133.4, C | - | 133.0, C |
| 13 | 7.18 dd (8.5, 2.5) | 123.6, CH | 7.35 dd ( | 123.2, CH |
| 14 | 7.06 dd (8.5, 2.5) | 131.5, CH | 7.1 dd ( | 131.4, CH |
| 15 | 7.37 (8.5,2.5) | 130.3, CH | 7.0 dd ( | 132.5, CH |
| 16 | 7.30 dd (8.5, 2.5) | 122.7, CH | 7.27 dd ( | 123.9, CH |
| 17 | 1.99 m | 37.1, CH | _ | 139.0, C |
| 18 | 1.11 m, 1.59 m | 24.8, CH2 | 7.71 br. d ( | 129.0, CH |
| 19 | 0.78 t (7.5) | 16.2, CH3 | 7.15 br t (7.2) | 128.6, CH |
| 20 | 0.77 d (7.5) | 12.3, CH3 | 7.29 br t (7.2) | 128.7, CH |
| 21 | 1.28 m, 2.15 m | 32.8, CH2 | 7.15 br t (7.2) | 128.6, CH |
| 22 | 3.50 m, 4.48 m | 47.2, CH2 | 7.71 br. d ( | 129.0, CH |
| 23 | - | 1.51 m, 2.11 m | 25.9, CH2 | |
| 24 | - | 172.0, C | 1.35 m, 1.74 m | 25.1, CH2 |
| 25 | 4.50 t (8.5) | 56.6, CH | 3.07 t (8.4), 3.28 m | 47.4, CH2 |
| 26 | 1.97 m | 31.8, CH | 7.78 d ( | NH |
| 27 | 0.84 d (6.5) | 19.4, CH3 | _ | 169.7, CO |
| 28 | 0.94 d (6.5) | 19.1, CH3 | 4.39 m | 56.1,CH |
| 29 | 7.6 d (8.5) | -, NH | 2.73 dd (11.4,10.8), 3.29 dd ( 11.4,3.6) | 37.0, CH2 |
| 30 | - | 166.2, C | - | 138.5, C |
| 31 | 6.85 d (15.5) | 122.3, CH | 7.12 br d (7.2) | 129.8, CH |
| 32 | 7.58 d (15.5) | 141.0, CH | 7.20 br t (7.2) | 129.3, CH |
| 33 | - | 136.3, C | 7.15 br t (7.2) | 130.7, CH |
| 34 | 7.39 br d (7.5) | 129.7, CH | 7.20 br t (7.2) | 129.3,CH |
| 35 | 7.57 br t (7.5) | 128.5, CH | 7.12 br d (7.2) | 129.8,CH |
| 36 | 7.07 br t (7.5) | 132.6, CH | 7.11 d (7.5) | _, NH |
| 37 | 7.39 br d (7.5) | 129.7, CH | - | 166.4, CO |
| 38 | 7.57 br t (7.5) | 128.5, CH | 6.65 d (15.0) | 120.0, CH |
| 39 | 7.53 d (15.0) | 142.7, CH | ||
| 40 | 136.2, C | |||
| 41,45 | 7.10 br d (7.2) | 129.0, CH | ||
| 42,44 | 7.20 br t (7.2) | 128 .6, CH | ||
| 43 | 7.07 br t (7.2) | 129.8, CH | ||
Figure 2(A) Key COSY and NOESY interactions in oxyphylline B (4); (B) Key HMBC interactions in oxyphylline B (4).
Figure 3(A) Key COSY and NOESY interactions in oxyphylline C (5); (B) Key HMBC interactions in oxyphylline C (5).
Antibacterial activity of the isolated compounds. Data are the Minimum Inhibitory Concentration (MIC, μg/mL).
| MIC (μg/mL) | ||||||
|---|---|---|---|---|---|---|
|
| ||||||
| Compound | ||||||
| 1 | 10 | 25 | 50 | 25 | 50 | 25 |
| 2 | 10 | 25 | 100 | 25 | 100 | 10 |
| 3 | 25 | 10 | 100 | 50 | 100 | 50 |
| 4 | 5 | 10 | 25 | 25 | 50 | 10 |
| 5 | 10 | 50 | 50 | 10 | 50 | 50 |
| Standard | 0.0002 | 0.0005 | 0.0003 | 0.0009 | 0.0021 | 0.0014 |
Figure 4Schematic diagram indicating study design.